AgeneBio is a development-stage CNS biopharmaceutical company developing innovative therapeutics aimed at preserving brain function for patients with neurological and psychiatric diseases. AgeneBio's novel pipeline of therapies is based on decades of research at Johns Hopkins University showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration. This overactivity is a characteristic feature of mild cognitive impairment due to Alzheimer’s disease. AgeneBio's Phase 2b candidate AGB101 is the first and only therapeutic being investigated to target hippocampal overactivity to slow progression to and delay the onset of Alzheimer's dementia. The HOPE4MCI trial is partially supported by a public/private partnership grant from NIA and awards from the Alzheimer's Drug Discovery Foundation. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage being investigated multiple neurological and psychiatric indications.
AgeneBio is presenting as part of the NIH Innovation Zone.